A case report
Search results for: diffuse systemic sclerosis
2013 ACR/ARHP Annual Meeting: Strides Made in Understanding Systemic Sclerosis
Greater knowledge of how vasculitis, fibrosis, and autoimmunity interact in these destructive diseases will result in better clinical management
ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
Understanding the role of autoantibodies in systemic sclerosis (SSc) may help predict the course of the disease and guide clinical trials
EULAR 2012: Systemic Sclerosis That Doesn’t Fit the Mold
This disease presents a range of hard-to-solve clinical difficulties.
Progress Continues in Systemic Sclerosis
Advances in genetics and potential therapies shed new light on the disease
FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations
The U.S. Food & Drug Administration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…
Case Report: A Patient Develops Scleroderma Renal Crisis
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…
Treatment Tips for Pulmonary Arterial Hypertension & ILD
CHICAGO—About 30 years ago, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) began to outpace renal crisis as the main causes of death in scleroderma (SSc). But treating these lung complications has proved vexing for clinicians. There is no easy way to predict who will develop PAH. There is no telltale antibody and no…
Researchers Test Belimumab in Scleroderma
A yearlong pilot study that evaluated the safety and efficacy of belimumab in a small group of patients with early diffuse systemic sclerosis found no significant difference in the number of adverse events between those treated with the drug and those who received a placebo. Currently, no drugs are approved specifically for the treatment of…
Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics
SAN DIEGO—Fibrosis affects all organ systems, but isn’t always systemic sclerosis. Experts on less common forms discussed patient presentations, diagnosis and treatment at the 2017 ACR/ARHP Annual Meeting in San Diego on Nov. 6. Retroperitoneal Fibrosis Formerly called Ormond’s disease, retroperitoneal fibrosis (RPF) is usually an IgG4-related disease, but has some unique characteristics, said John…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »